A Phase 2 interventional study of Biological/Vaccine: BC-819 in Pancreas, Adenocarcinoma, sponsored by Anchiano Therapeutics Israel Ltd.. Terminated at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-01.
Sponsored by Anchiano Therapeutics Israel Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Adenocarcinoma with a site in Israel — none open to participants now, 3 under way, 2 of them phase 3. Adenocarcinoma · Israel.
Among the 10 studies in Adenocarcinoma with a site in Israel, this one is the 10th largest by enrollment, is the only one that started in 2011, is one of 4 in phase 2, and was the 3rd registered.
620 studies on the registry are indexed under Adenocarcinoma; 148 are open to participants now.
Browse Adenocarcinoma studies →None of the 10 studies in Adenocarcinoma with a site in Israel is open now. The open studies under Adenocarcinoma, anywhere →
Of the 111 Adenocarcinoma studies recruiting now, 82 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 57 across 490 interventional studies indexed under Adenocarcinoma.
Median enrollment 367 across the 10 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 10 most frequent:
Anchiano Therapeutics Israel Ltd. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Anchiano Therapeutics Israel Ltd. has 1 study filed under Adenocarcinoma — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Adenocarcinoma with a site in Israel, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, open label, randomized, phase 2b study, designed to evaluate the safety and efficacy of patients with locally advanced pancreatic adenocarcinoma following intratumoral administration of BC-819 and intravenously administered gemcitabine. Intratumoral injections of BC-819 will be performed using endoscopic ultrasound (EUS).
Primary Objective: To assess the effect of intratumoral endoscopic ultrasound injection of BC-819 administered with intravenous gemcitabine on progression-free survival.
Secondary Objectives: To compare the effects of intratumoral injection of BC-819 administered in combination with intravenous gemcitabine vs. intravenous gemcitabine alone on:
Overall survival, Response rate, Resectability of the target tumor lesion, Quality of life, Safety, Serological Tumor Marker: CA 19-9, Duration of response, Failure-free survival
BC-819 (also known as DTA-H19) is a double-stranded DNA plasmid, 4,560 base pairs (bp) in length, carrying the gene for the Diphtheria toxin A (DT-A) chain under the regulation of the H19 promoter. This is a Targeted Cancer Therapy; DT-A chain expression is triggered by the presence of H19 transcription factors that are only up-regulated in tumor cells. The selective initiation of toxin expression results in selective tumor cell destruction via inhibition of protein synthesis selectively in the tumor cell, enabling highly targeted cancer treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate hematological, renal, and hepatic function
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
gemcitabine dose of 1000mg/m2 + 8 mg of BC-819
Biological: Biological/Vaccine: BC-819
gemcitabine dose of 1000mg/m2 + 12 mg of BC-819
Biological: Biological/Vaccine: BC-819
Drug pages: Biological Products · Inodiftagene vixteplasmid
Post screening and prior to randomization, all patients will receive gemcitabine by IV infusion at a dose of 1000mg/m2 once weekly for four weeks. They may also enter the study if they received up to 4 doses of gemcitabine before entering the study. In this case, they will be randomized immediately provided there is no evidence of disease progression. After randomization patients will receive 6 weekly IV infusions of gemcitabine at a dose of 1000mg/m2 + 7 intratumoral injections of BC-819 (8 mg or 12 mg according to allocations by randomization)
Also known as: DTA-H19, inodiftagene vixteplasmid
Progression-free Survival (PFS)
To compare the effect of intratumoral endoscopic ultrasound injection of BC-819 administered with intravenous gemcitabine on progression-free survival. PFS was defined as the time from the date of consent until objective tumor progression or death. Median PFS by Kaplan-Meier analysis was used for evaluation. The target tumor lesion was identified and the longest diameter of the target lesion was measured according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines. For disease evaluations after treatment, scans conducted at baseline that were used for tumor measurements were repeated.
Time frame: 24 months
Overall Survival (OS)
OS was calculated from the date of consent until death due to any cause.
Time frame: 24 months
Response Rate of Target Lesion
Response rate will be assessed both for the primary target tumor lesion alone and overall, including development of metastases. Target tumor lesions are identified and the longest diameter of the target lesion is measured by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines. Complete response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also show an increase of at least 5 mm. Stable Disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: 8 weeks
Resectability of the Target Tumor Lesion
Resectability of the target tumor lesion was determined by CT/MRI as defined in the National Comprehensive Cancer network (NCCN) guidelines. Resectable tumors have no arterial tumor contact (celiac axis \[CA\], superior mesenteric artery \[SMA\], or common hepatic artery \[CHA\]) and no tumor contact with the superior mesenteric vein (SMV) or portal vein (PV) or ≤180° contact without vein contour irregularity. \*Not Applicable refers to another clinically significant abnormality that interfered with resectability determination of the target tumor lesion.
Time frame: an average of 16 weeks
Quality of Life (QoL) Assessed by Karnofsky Performance Status (KPS)
Quality of life will be assessed by the The Karnofsky Performance Status (KPS) Index. KPS scores over time will be compared to those at baseline and changes from baseline will be presented. KPS scores are on a scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100) of 0 (dead) to 100 (Normal no complaints; no evidence of disease).
Time frame: Screening, Visit 4 (post gemcitabine induction), Visit 9 (5 weeks), Visit 13 (9 weeks)
Quality of Life Using the Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire
The FACT-G is a 27-item compilation of general questions divided into 4 primary QoL domains: physical well-being, social/family well-being, emotional well-being and functional well-being. The total FACT-G scores will be summarized by descriptive statistics (e.g., n, mean, median, standard deviation and range). The individual FACT-G score will be presented by frequency and percentage. Scores range from 0-108. High total scores represent better general QoL.
Time frame: Screening, Visit 4 (post gemcitabine induction), Visit 9 (5 weeks), Visit 13 (9 weeks), every 6 months after Visit 13
Serological Tumor Marker: CA 19-9
Serum was collected for quantitative measurement of CA 19-9.
Time frame: 24 months
Extent of Exposure - Gemcitabine Total Exposure (g)
Measured by the average and median number of exposure of the patients to BC-819 and gemcitabine.
Time frame: 24 months
Extent of Exposure - Gemcitabine Total Number of Treatments
Measured by the average and median number of treatments of the patients to BC-819 and gemcitabine.
Time frame: 24 months
Extent of Exposure - BC-819 Total Exposure (mg)
Measured by the average and median exposure of the patients to BC-819 and gemcitabine.
Time frame: 24 months
Extent of Exposure - BC-819 Total Number of Treatments
Measured by the average and median number of treatments of the patients to BC-819 and gemcitabine.
Time frame: 24 months
| Milestone | 8 mg BC-819 and Gemcitabine | 12 mg BC-819 and Gemcitabine |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
To compare the effect of intratumoral endoscopic ultrasound injection of BC-819 administered with intravenous gemcitabine on progression-free survival. PFS was defined as the time from the date of consent until objective tumor progression or death. Median PFS by Kaplan-Meier analysis was used for evaluation. The target tumor lesion was identified and the longest diameter of the target lesion was measured according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines. For disease evaluations after treatment, scans conducted at baseline that were used for tumor measurements were repeated.
| months | 8 mg BC-819 and Gemcitabine | 12 mg BC-819 and Gemcitabine |
|---|---|---|
| Progression-free Survival (PFS) | 9.3 (2.6 to 26.3) | 7.6 (6.3 to 10.7) |
OS was calculated from the date of consent until death due to any cause.
| years | 8 mg BC-819 and Gemcitabine | 12 mg BC-819 and Gemcitabine |
|---|---|---|
| Overall Survival (OS) | 9.9 (5.4 to 26.4) | 8.5 (6.8 to NA) |
Response rate will be assessed both for the primary target tumor lesion alone and overall, including development of metastases. Target tumor lesions are identified and the longest diameter of the target lesion is measured by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines. Complete response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also show an increase of at least 5 mm. Stable Disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| Participants | 8 mg BC-819 and Gemcitabine | 12 mg BC-819 and Gemcitabine |
|---|---|---|
| Complete Response | 0 | 0 |
| Partial Response | 1 | 0 |
| Stable Disease | 2 | 6 |
| Progressive Disease | 1 | 0 |
| Inevaluable - Missing Postbaseline Scan | 2 | 0 |
Resectability of the target tumor lesion was determined by CT/MRI as defined in the National Comprehensive Cancer network (NCCN) guidelines. Resectable tumors have no arterial tumor contact (celiac axis \[CA\], superior mesenteric artery \[SMA\], or common hepatic artery \[CHA\]) and no tumor contact with the superior mesenteric vein (SMV) or portal vein (PV) or ≤180° contact without vein contour irregularity. \*Not Applicable refers to another clinically significant abnormality that interfered with resectability determination of the target tumor lesion.
| Participants | 8 mg BC-819 and Gemcitabine | 12 mg BC-819 and Gemcitabine |
|---|---|---|
| Not Resectable | 5 | 6 |
| Not Applicable* | 1 | 0 |
Quality of life will be assessed by the The Karnofsky Performance Status (KPS) Index. KPS scores over time will be compared to those at baseline and changes from baseline will be presented. KPS scores are on a scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100) of 0 (dead) to 100 (Normal no complaints; no evidence of disease).
| score on a scale | 8 mg BC-819 and Gemcitabine | 12 mg BC-819 and Gemcitabine |
|---|---|---|
| Screening | 90 (80 to 100) | 90 (80 to 100) |
| Visit 4 (pre-randomization) | 90 (90 to 90) | 85 (80 to 100) |
| Visit 9 (Week 5) | 80 (80 to 90) | 90 (80 to 90) |
| Visit 13 (Week 9) | 80 (80 to 90) | 90 (80 to 90) |
The FACT-G is a 27-item compilation of general questions divided into 4 primary QoL domains: physical well-being, social/family well-being, emotional well-being and functional well-being. The total FACT-G scores will be summarized by descriptive statistics (e.g., n, mean, median, standard deviation and range). The individual FACT-G score will be presented by frequency and percentage. Scores range from 0-108. High total scores represent better general QoL.
| units on a scale | 8 mg BC-819 and Gemcitabine | 12 mg BC-819 and Gemcitabine |
|---|---|---|
| Screening | 71.8 ± 11.8 | 81.9 ± 14.0 |
| Max change from baseline | -1.3 ± 18.5 | -2.5 ± 18.8 |
Serum was collected for quantitative measurement of CA 19-9.
| U/mL | 8 mg BC-819 and Gemcitabine | 12 mg BC-819 and Gemcitabine |
|---|---|---|
| Screening | 1025.9 ± 1090.6 | 587.7 ± 340.1 |
| Nadir value | 369.8 ± 511.7 | 149.1 ± 97.0 |
| Change at Nadir | -656.1 ± 887.7 | -438.6 ± 252.2 |
Measured by the average and median number of exposure of the patients to BC-819 and gemcitabine.
| g | 8 mg BC-819 and Gemcitabine | 12 mg BC-819 and Gemcitabine |
|---|---|---|
| Extent of Exposure - Gemcitabine Total Exposure (g) | 20.1 ± 9.5 | 21.3 ± 11.9 |
Measured by the average and median number of treatments of the patients to BC-819 and gemcitabine.
| number of treatments | 8 mg BC-819 and Gemcitabine | 12 mg BC-819 and Gemcitabine |
|---|---|---|
| Extent of Exposure - Gemcitabine Total Number of Treatments | 17.3 ± 14.9 | 15.3 ± 12.7 |
Measured by the average and median exposure of the patients to BC-819 and gemcitabine.
| mg | 8 mg BC-819 and Gemcitabine | 12 mg BC-819 and Gemcitabine |
|---|---|---|
| Extent of Exposure - BC-819 Total Exposure (mg) | 68.0 ± 29.8 | 118.0 ± 41.2 |
Measured by the average and median number of treatments of the patients to BC-819 and gemcitabine.
| number of treatments | 8 mg BC-819 and Gemcitabine | 12 mg BC-819 and Gemcitabine |
|---|---|---|
| Extent of Exposure - BC-819 Total Number of Treatments | 10.7 ± 8.4 | 11.2 ± 6.0 |
Collected over 24 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 8 mg BC-819 and Gemcitabine | 0/6 (0%) | 5/6 (83.3%) | 5/6 (83.3%) |
| 12 mg BC-819 and Gemcitabine | 1/6 (16.7%) | 5/6 (83.3%) | 5/6 (83.3%) |
| Event | 8 mg BC-819 and Gemcitabine | 12 mg BC-819 and Gemcitabine |
|---|---|---|
| Bile duct obstructionHepatobiliary disorders | 1/6 | 2/6 |
| PneumoniaInfections and infestations | 1/6 | 0/6 |
| Generalized EdemaGeneral disorders | 1/6 | 0/6 |
| Gastrointestinal obstructionGastrointestinal disorders | 1/6 | 0/6 |
| Clostridium difficile colitisInfections and infestations | 1/6 | 0/6 |
| DehydrationMetabolism and nutrition disorders | 1/6 | 0/6 |
| Epigastric painGastrointestinal disorders | 1/6 | 0/6 |
| Frequent bowel movementGastrointestinal disorders | 1/6 | 0/6 |
| DuodenitisGastrointestinal disorders | 1/6 | 0/6 |
| Stent malfunctionProduct Issues | 0/6 | 1/6 |
| Event | 8 mg BC-819 and Gemcitabine | 12 mg BC-819 and Gemcitabine |
|---|---|---|
| NauseaGastrointestinal disorders | 4/6 | 4/6 |
| FatigueGeneral disorders | 4/6 | 1/6 |
| VomitingGastrointestinal disorders | 3/6 | 1/6 |
| ConstipationGastrointestinal disorders | 3/6 | 1/6 |
| Increased blood bilirubinInvestigations | 0/6 | 3/6 |
| Decreased appetiteMetabolism and nutrition disorders | 3/6 | 1/6 |
| NauseaGastrointestinal disorders | 3/6 | 3/6 |
| Abdominal painGastrointestinal disorders | 2/6 | 1/6 |
| DiarrheaGastrointestinal disorders | 2/6 | 1/6 |
| AstheniaGeneral disorders | 2/6 | 1/6 |
| Age, Continuous(years) | 8 mg BC-819 and Gemcitabine | 12 mg BC-819 and Gemcitabine | Total |
|---|---|---|---|
| Mean | 72.2 ± 6.7 | 62.2 ± 13.0 | 67.4 ± 11.3 |
| Sex: Female, Male(Participants) | 8 mg BC-819 and Gemcitabine | 12 mg BC-819 and Gemcitabine | Total |
|---|---|---|---|
| Female | 4 | 1 | 5 |
| Male | 2 | 5 | 7 |
| Race (NIH/OMB)(Participants) | 8 mg BC-819 and Gemcitabine | 12 mg BC-819 and Gemcitabine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 5 | 6 | 11 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
Ran from Sep 2011 to primary completion in Jan 2013, 16 months.
Results were first posted in Nov 2019, 6 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Biological Products · Inodiftagene vixteplasmid
Anchiano Therapeutics Israel Ltd.